Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a single transaction detail:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Acquisition of ADSs via dividend reinvestment.
- Price: $43.87 per ADS.
- Volume: 251.123 ADSs.
- Date: July 14, 2016.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely discloses a routine transaction under the US Deferred Performance Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The transaction was an acquisition of ADSs following the reinvestment of dividends paid to shareholders on July 14, 2016, for Dr. M M Slaoui, Chairman of Global Vaccines.
Investor Verification Points
- Verify the total number of ADSs held by Dr. M M Slaoui post-transaction to assess insider ownership levels.
- Confirm the dividend reinvestment terms of the US Deferred Performance Plan referenced in the transaction.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.